NCT03613857View on ClinicalTrials.gov

Effect of Diabetes and Hepatic Enzymes Mutation on Clopidogrel VS Ticagrelor Activity in Myocardial Infarction (MI) Patients Undergoing Primary Percutaneous Coronary Intervention (PCI)

CompletedOBSERVATIONAL

Enrollment

1,022

Participants

Timeline

Start Date

April 15, 2017

Primary Completion Date

July 28, 2018

Study Completion Date

July 28, 2018

Conditions

Myocardial Infarction

Interventions

DRUG

Clopidogrel

8 tablets 75 mg clopidogrel loading dose before PCI

DRUG

Ticagrelor 90mg

2 tablets 90 mg brilique before PCI

Trial Locations (1)

01234567

Faculty of pharmacy Cairo university, Cairo

All Listed Sponsors

lead

Cairo University

OTHER

NCT03613857 - Effect of Diabetes and Hepatic Enzymes Mutation on Clopidogrel VS Ticagrelor Activity in Myocardial Infarction (MI) Patients Undergoing Primary Percutaneous Coronary Intervention (PCI) | Biotech Hunter | Biotech Hunter